The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis
Abstract
Thyroid cancer is the most common malignant tumor of the endocrine system and accounts for approximately 1% of all newly diagnosed cancer cases. The most frequent type of thyroid malignancy is papillary carcinoma, which constitutes approximately 80% of all cases. Papillary carcinomas frequently have genetic alterations leading to the activation of the MAPK signal pathway. Those include RET/PTC rearrangement and point mutations of the BRAF and RAS genes. Mutations in these genes are found in over 70% of papillary carcinomas and they rarely overlap in the same tumor. Frequent genetic alterations in follicular carcinomas, the second most common type of thyroid malignancy, include RAS mutations and PAX8-PPAR gamma rearrangement. RET point mutations are crucial for the development of medullary thyroid carcinomas. Many of these mutations, particularly those leading to the activation of the MAPK pathway, are being actively explored as therapeutic targets for thyroid cancer. Detection of these genetic alterations using molecular techniques is important for preoperative fine-needle aspiration diagnosis, prognosis and treatment of thyroid cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,369
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Sherman, S. I., & Tuttle, R. M. (2006) · Thyroid · doi:10.1089/thy.2006.16.109 · Cited by 2,016
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,510
Self-citationBRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
Pathology and genetics of tumours of endocrine organs
DeLellis, R. A. (2004) · Cited by 1,122
Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030838 · Cited by 1,042
Self-citationBRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0987 · Cited by 993
Grieco, M., Santoro, M., Berlingieri, M. T., Melillo, R. M., Donghi, R., Bongarzone, I., Pierotti, M. A., Della Ports, G., Fusco, A., & Vecchiot, G. (1990) · Cell · doi:10.1016/0092-8674(90)90659-3 · Cited by 959
BRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 922
PAX8-PPAR γ 1 Fusion in Oncogene Human Thyroid Carcinoma
Kroll, T. G., Sarraf, P., Pecciarini, L., Chen, C.-J., Mueller, E., Spiegelman, B. M., & Fletcher, J. A. (2000) · Science · doi:10.1126/science.289.5483.1357 · Cited by 784
Nikiforova, M. N., Lynch, R. A., Biddinger, P. W., Alexander, E. K., Dorn, G. W., Tallini, G., Kroll, T. G., & Nikiforov, Y. E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021907 · Cited by 713
Self-citationBRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
Soares, P., Trovisco, V., Rocha, A. S., Lima, J., Castro, P., Preto, A., Máximo, V., Botelho, T., Seruca, R., & Sobrinho-Simões, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206706 · Cited by 679
Nikiforov, Y. E., Rowland, J. M., Bove, K. E., Monforte-Muñoz, H., & Fagin, J. A. (1997) · PubMed · Cited by 666
Self-citationHigh prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
Fagin, J. A., Matsuo, K., Karmakar, A., Chen, D. L., Tang, S. H., & Koeffler, H. P. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116168 · Cited by 649
Volante, M., Collini, P., Nikiforov, Y. E., Sakamoto, A., Kakudo, K., Katoh, R., Lloyd, R. V., LiVolsi, V. A., Papotti, M., Sobrinho-Simoes, M., et al. (2007) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3180309e6a · Cited by 619
Self-citationCarlomagno, F., Vitagliano, D., Guida, T., Ciardiello, F., Tortora, G., Vecchio, G., Ryan, A. J., Fontanini, G., Fusco, A., & Santoro, M. M. (2002) · PubMed · Cited by 569
Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers
Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T. I., Ohtsuru, A., Saenko, V. A., Kanematsu, T., & Yamashita, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030305 · Cited by 533
Adeniran, A. J., Zhu, Z., Gandhi, M., Steward, D. L., Fidler, J. P., Giordano, T. J., Biddinger, P. W., & Nikiforov, Y. E. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000176432.73455.1b · Cited by 495
Self-citationRET/PTC Rearrangement in Thyroid Tumors
Nikiforov, Y. E. (2002) · Endocrine Pathology · doi:10.1385/ep:13:1:03 · Cited by 489
Self-citationOncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer
Ciampi, R., Knauf, J. A., Kerler, R., Gandhi, M., Zhu, Z., Nikiforova, M. N., Rabes, H. M., Fagin, J. A., & Nikiforov, Y. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523237 · Cited by 461
Self-citationRabes, H. M., Demidchik, E. P., Sidorow, J. D., Lengfelder, E., Beimfohr, C., Hoelzel, D., & Klugbauer, S. (2000) · PubMed · Cited by 428
Hou, P., Liu, D., Shan, Y., Hu, S., Studeman, K., Condouris, S., Wang, Y., Trink, A., El-Naggar, A. K., Tallini, G., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1125 · Cited by 418
High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis.
Lemoine, N. R., Mayall, E. S., Wyllie, F. S., Williams, E. D., Goyns, M. H., Stringer, B. M. J., & Wynford‐Thomas, D. (1989) · PubMed · Cited by 417
Knauf, J. A., Ma, X., Smith, E. P., Zhang, L., Mitsutake, N., Liao, X.-H., Refetoff, S., Nikiforov, Y. E., & Fagin, J. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0047 · Cited by 414
Self-citationRet oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.
Santoro, M., Carlomagno, F., Hay, I. D., Herrmann, M. A., Grieco, M., Melillo, R., Pierotti, M. A., Bongarzone, I., Della Porta, G., & Berger, N. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115743 · Cited by 390
Leenhardt, L., Grosclaude, P., & Chérié-Challine, L. (2004) · Thyroid · doi:10.1089/thy.2004.14.1056 · Cited by 384
Giordano, T. J., Kuick, R., Thomas, D. G., Misek, D. E., Vinco, M., Sanders, D., Zhu, Z., Ciampi, R., Roh, M., Shedden, K., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208822 · Cited by 383
Self-citationRiesco-Eizaguirre, G., Gutiérrez-Martínez, P., García-Cabezas, M. A., Nistal, M., & Santisteban, P. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01119 · Cited by 376
Zhu, Z., Gandhi, M., Nikiforova, M. N., Fischer, A. H., & Nikiforov, Y. E. (2003) · American Journal of Clinical Pathology · doi:10.1309/nd8d-9laj-trct-g6qd · Cited by 371
Self-citationDonghi, R., Longoni, A., Pilotti, S., Michieli, P., Della Porta, G., & Pierotti, M. A. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116385 · Cited by 370
ras Mutations Are Associated With Aggressive Tumor Phenotypes and Poor Prognosis in Thyroid Cancer
Garcia-Rostan, G., Zhao, H., Camp, R. L., Pollan, M., Herrero, A., Pardo, J., Wu, R., Carcangiu, M. L., Costa, J., & Tallini, G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.130 · Cited by 368
Santoro, M. M., Dathan, N. A., Berlingieri, M. T., Bongarzone, I., Paulin, C., Grieco, M., Pierotti, M. A., Vecchio, G., & Fusco, A. (1994) · PubMed · Cited by 366
BRAF mutations are associated with some histological types of papillary thyroid carcinoma
Trovisco, V., Vieira de Castro, I., Soares, P., Máximo, V., Silva, P., Magalhães, J., Abrosimov, A., Guiu, X. M., & Sobrinho‐Simões, M. (2004) · The Journal of Pathology · doi:10.1002/path.1511 · Cited by 363
Point Mutations of Ras Oncogenes are an Early Event in Thyroid Tumorigenesis
Namba, H., Rubin, S. A., & Fagin, J. A. (1990) · Molecular Endocrinology · doi:10.1210/mend-4-10-1474 · Cited by 356
Zhu, Z., Gandhi, M., Nikiforova, M. N., Fischer, A. H., & Nikiforov, Y. E. (2003) · American Journal of Clinical Pathology · doi:10.1309/nd8d9lajtrctg6qd · Cited by 355
Self-citationPAX8-PPARγ Rearrangement in Thyroid Tumors: RT-PCR and Immunohistochemical Analyses
Nikiforova, M. N., Biddinger, P. W., Caudill, C. M., Kroll, T. G., & Nikiforov, Y. E. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200208000-00006 · Cited by 349
Self-citationMutation of the PIK3CA Gene in Anaplastic Thyroid Cancer
García-Rostán, G., Costa, A. M., Pereira-Castro, I., Salvatore, G., Hernandez, R., Hermsem, M. J. A., Herrero, A., Fusco, A., Cameselle-Teijeiro, J., & Santoro, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4259 · Cited by 338
Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors.
Dahia, P. L. M., Marsh, D. J., Zheng, Z., Zedenius, J., Komminoth, P., Frisk, T., Wallin, G., Parsons, R. E., Longy, M., Larsson, C., et al. (1997) · PubMed · Cited by 327
Expression of PAX8-PPARγ1 Rearrangements in Both Follicular Thyroid Carcinomas and Adenomas
Marques, A. R., Espadinha, C., Catarino, A. L., Moniz, S., Pereira, T., Sobrinho, L. G., & Leite, V. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.8.8756 · Cited by 305
Kim, D. W., Jo, Y. S., Jung, H. S., Chung, H. K., Song, J. H., Park, K. C., Park, S. H., Hwang, J. H., Rha, S. Y., Kweon, G. R., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2845 · Cited by 279
β-Catenin Dysregulation in Thyroid Neoplasms
Garcia-Rostan, G., Camp, R. L., Herrero, A., Carcangiu, M. L., Rimm, D. L., & Tallini, G. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64045-x · Cited by 277
Elisei, R., Romei, C., Vorontsova, T., Cosci, B., Veremeychik, V., Kuchinskaya, E., Basolo, F., Demidchik, E. P., Miccoli, P., Pinchera, A., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7678 · Cited by 275
Mulligan, L. M., MARSH, D. J., ROBINSON, B. G., SCHUFFENECKER, I., ZEDENIUS, J., LIPS, C. J. M., GAGEL, R. F., TAKAI, S. ‐., NOLL, W. W., FINK, M., et al. (1995) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1995.tb01208.x · Cited by 272
Máximo, V., Soares, P., Lima, J., Cameselle-Teijeiro, J., & Sobrinho-Simões, M. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61132-7 · Cited by 271
Frattini, M., Ferrario, C., Bressan, P., Balestra, D., De Cecco, L., Mondellini, P., Bongarzone, I., Collini, P., Gariboldi, M., Pilotti, S., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207980 · Cited by 266
Presence of mutations in all three ras genes in human thyroid tumors.
Suarez, H. G., Ja, D. V., Severino, M. E., Caillou, B., Schlumberger, M. J., Tubiana, M., Parmentier, C., & Monier, R. (1990) · PubMed · Cited by 262
BRAFV599EMutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas
Puxeddu, E., Moretti, S., Elisei, R., Romei, C., Pascucci, R., Martinelli, M., Marino, C., Avenia, N., Rossi, E. D., Fadda, G., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031425 · Cited by 260
Salvatore, G., Giannini, R., Faviana, P., Caleo, A., Migliaccio, I., Fagin, J. A., Nikiforov, Y. E., Troncone, G., Palombini, L., Basolo, F., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032221 · Cited by 259
Self-citationTrovisco, V., Soares, P., Preto, A., de Castro, I. V., Lima, J., Castro, P., Máximo, V., Botelho, T., Moreira, S., Meireles, A. M., et al. (2005) · Virchows Archiv · doi:10.1007/s00428-005-1236-0 · Cited by 253
Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis
Hansford, J. R., & Mulligan, L. M. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.11.817 · Cited by 241
Kim, T. Y., Kim, W. B., Rhee, Y. S., Song, J. Y., Kim, J. M., Gong, G., Lee, S., Kim, S. Y., Kim, S. C., Hong, S. J., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02605.x · Cited by 238
Bongarzone, I., Monzini, N., Borrello, M. G., Carcano, C., Ferraresi, G., Arighi, E., Mondellini, P., Della Porta, G., & Pierotti, M. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.358-366.1993 · Cited by 236
Nikiforov, Y. E. (2004) · Endocrine Pathology · doi:10.1385/ep:15:4:319 · Cited by 234
Self-citationFenton, C. L., Lukes, Y., Nicholson, D., Dinauer, C. A., Francis, G. L., & Tuttle, R. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6472 · Cited by 225
RET Oncogene Activation in Papillary Thyroid Carcinoma
Tallini, G., Asa, S. L., & Fuller, G. N. (2001) · Advances in Anatomic Pathology · doi:10.1097/00125480-200111000-00005 · Cited by 223
Prevalence of Ras mutations in thyroid neoplasia
Esapa, C. T., Johnson, S. J., Kendall‐Taylor, P., Lennard, T. W. J., & Harris, P. E. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00704.x · Cited by 220
Fahey, T. J. (2006) · Yearbook of Surgery · doi:10.1016/s0090-3671(08)70420-8 · Cited by 218
Bongarzone, I., Butti, M. G., Coronelli, S., Borrello, M. G., Santoro, M., Mondellini, P., Pilotti, S., Fusco, A., Porta, G., & Pierotti, M. A. (1994) · PubMed · Cited by 215
Máximo, V, Botelho, T., Capela, J., Soares, P., Lima, J., Taveira, A., Amaro, T., Barbosa, A. P., Preto, A., Harach, H. R., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602547 · Cited by 214
Zhu, Z., Ciampi, R., Nikiforova, M. N., Gandhi, M., & Nikiforov, Y. E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1006 · Cited by 209
Self-citationDwight, T., Thoppe, S. R., Foukakis, T., Lui, W. O., Wallin, G., Höög, A., Frisk, T., Larsson, C., & Zedenius, J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021690 · Cited by 208
Cohen, Y., Rosenbaum, E., Clark, D. P., Zeiger, M. A., Umbricht, C. B., Tufano, R. P., Sidransky, D., & Westra, W. H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0273 · Cited by 207
The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway
Saavedra, H. I., Knauf, J. A., Shirokawa, J. M., Wang, J., Ouyang, B., Elisei, R., Stambrook, P. J., & Fagin, J. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203723 · Cited by 186
BRAF mutations in an Italian cohort of thyroid cancers
Fugazzola, L., Mannavola, D., Cirello, V., Vannucchi, G., Muzza, M., Vicentini, L., & Beck‐Peccoz, P. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02089.x · Cited by 184
Knauf, J. A., Kuroda, H., Basu, S., & Fagin, J. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206602 · Cited by 181
Cheung, C. C. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.5.2187 · Cited by 180
Genetic and Biological Subgroups of Low-Stage Follicular Thyroid Cancer
French, C. A., Alexander, E. K., Cibas, E. S., Nose, V., Laguette, J., Faquin, W., Garber, J., Moore, F., Fletcher, J. A., Larsen, P. R., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63902-8 · Cited by 175
Begum, S., Rosenbaum, E., Henrique, R., Cohen, Y., Sidransky, D., & Westra, W. H. (2004) · Modern Pathology · doi:10.1038/modpathol.3800198 · Cited by 175
Ras Oncogene Mutations in Benign and Malignant Thyroid Neoplasms
KARGA, H., LEE, J.-K., VICKERY, A. L., THOR, A., GAZ, R. D., & JAMESON, J. L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-4-832 · Cited by 175
Wang, Y., Hou, P., Yu, H., Wang, W., Ji, M., Zhao, S., Yan, S., Sun, X., Liu, D., Shi, B., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2019 · Cited by 172
Klugbauer, S., & Rabes, H. M. (1999) · Oncogene · doi:10.1038/sj.onc.1202824 · Cited by 172
BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma
Salvatore, G., De Falco, V., Salerno, P., Nappi, T. C., Pepe, S., Troncone, G., Carlomagno, F., Melillo, R. M., Wilhelm, S. M., & Santoro, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2378 · Cited by 172
Bongarzone, I., Monzini, N., Borrello, M. G., Carcano, C., Ferraresi, G., Arighi, E., Mondellini, P., Della Porta, G., & Pierotti, M. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.358 · Cited by 166
Stepwise Participation of p53 Gene Mutation During Dedifferentiation of Human Thyroid Carcinomas
Dobashi, Y., Sugimura, H., Sakamoto, A., Mernyei, M., Mori, M., Oyama, T., & Machinami, R. (1994) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199403010-00003 · Cited by 164
Basolo, F., Pisaturo, F., Pollina, L. E., Fontanini, G., Elisei, R., Molinaro, E., Iacconi, P., Miccoli, P., & Pacini, F. (2000) · Thyroid · doi:10.1089/thy.2000.10.19 · Cited by 155
Nakata, T., Kitamura, Y., Shimizu, K., Tanaka, S., Fujimori, M., Yokoyama, S., Ito, K., & Emi, M. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199906)25:2<97::aid-gcc4>3.0.co;2-l · Cited by 154
Giordano, T. J., Au, A. Y. M., Kuick, R. D., Thomas, D. G., Rhodes, D. R., Wilhelm, K. G., Vinco, M., Misek, D. E., Sanders, D., Zhu, Z., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2039 · Cited by 152
Self-citationMoretti, F., Farsetti, A., Soddu, S., Misiti, S., Crescenzi, M., Filetti, S., Andreoli, M., Sacchi, A., & Pontecorvi, A. (1997) · Oncogene · doi:10.1038/sj.onc.1200887 · Cited by 150
RET and NTRK1 proto‐oncogenes in human diseases
Alberti, L., Carniti, C., Miranda, C., Roccato, E., & Pierotti, M. A. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10252 · Cited by 147
Herbst, R. S., Heymach, J. V., O’Reilly, M. S., Onn, A., & Ryan, A. J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.2.239 · Cited by 145
New therapeutic approaches for metastatic thyroid carcinoma
Baudin, E., & Schlumberger, M. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70034-7 · Cited by 143
Unger, K., Zitzelsberger, H. F., Salvatore, G., Santoro, M. M., Ti, B., Braselmann, H., Kastner, P., Zurnadzhy, L., Tronko, N., Hutzler, P., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031870 · Cited by 132
Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method.
Ishizaka, Y., Kobayashi, S. S., Ushijima, T., Hirohashi, S., Sugimura, T., & Nagao, M. (1991) · PubMed · Cited by 131
Localization of the Human β-Catenin Gene (CTNNB1) to 3p21: A Region Implicated in Tumor Development
Kraus, C. S., Liehr, T., Hülsken, J., Behrens, J., Birchmeier, W., Grzeschik, K., & Ballhausen, W. G. (1994) · Genomics · doi:10.1006/geno.1994.1493 · Cited by 130
Fagin, J. A. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.5.0838 · Cited by 130
Klugbauer, S., Demidchik, E. P., Lengfelder, E., & Hm, R. (1998) · PubMed · Cited by 128
Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas
Manenti, G., Pilotti, S., Re, F. C., Porta, G., & Pierotti, M. A. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90130-9 · Cited by 126
N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma.
Hara, H., Fulton, N. C., YASHIRO, T., Ito, K., DeGroot, L. J., & Kaplan, E. L. (1994) · PubMed · Cited by 124
Ward, L. S., Brenta, G., Medvedovic, M., & Fagin, J. A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4550 · Cited by 112
Powell, J. G., Wang, X., Allard, B. L., Şahin, M., Wang, X.-L., HAY, I. D., Hiddinga, H. J., Deshpande, S. S., Kroll, T. G., Grebe, S. K. G., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207399 · Cited by 106
Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin
Motoi, N., Sakamoto, A., Yamochi, T., Horiuchi, H., Motoi, T., & Machinami, R. (2000) · Pathology - Research and Practice · doi:10.1016/s0344-0338(00)80015-1 · Cited by 106
Targeting BRAF in thyroid cancer
Espinosa, A. V., Porchia, L. M., & Ringel, M. D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603520 · Cited by 104
Prevalence of Activating ras Mutations in Morphologically Characterized Thyroid Nodules
Ezzat, S., Zheng, L., KOLENDA, J., SAFARIAN, A., Freeman, J. L., & Asa, S. L. (1996) · Thyroid · doi:10.1089/thy.1996.6.409 · Cited by 98
Fagin, J. A., Tang, S., Zeki, K., Lauro, R. D., Fusco, A., & Gonsky, R. (1996) · PubMed · Cited by 93
Hou, P., Liu, D., & Xing, M. (2007) · Cell Cycle · doi:10.4161/cc.6.3.3818 · Cited by 87
RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma
Corvi, R., Berger, N., Balczon, R., & Romeo, G. (2000) · Oncogene · doi:10.1038/sj.onc.1203772 · Cited by 86
Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer
Santoro, M., & Carlomagno, F. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0073 · Cited by 79
Carta, C., Moretti, S., Passeri, L., Barbi, F., Avenia, N., Cavaliere, A., Monacelli, M., Macchiarulo, A., Santeusanio, F., Tartaglia, M., et al. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02401.x · Cited by 79
HOOK3-RET : a novel type of RET/PTC rearrangement in papillary thyroid carcinoma
Ciampi, R., Giordano, T. J., Wikenheiser‐Brokamp, K. A., Koenig, R. J., & Nikiforov, Y. E. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0039 · Cited by 79
Self-citationSalassidis, K., Bruch, J., Zitzelsberger, H. F., Lengfelder, E., Kellerer, A. M., & Bauchinger, M. (2000) · PubMed · Cited by 78
INGN 201 (Advexin®): adenoviral p53 gene therapy for cancer
Gabrilovich, D. I. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.8.823 · Cited by 74
Klugbauer, S., Jauch, A. T., Lengfelder, E., Demidchik, E. P., & Hm, R. (2000) · PubMed · Cited by 73
Mutations of p53 in Thyroid Carcinoma with an Insular Component
Takeuchi, Y., Daa, T., Kashima, K., Yokoyama, S., Nakayama, I., & Noguchi, S. (1999) · Thyroid · doi:10.1089/thy.1999.9.377 · Cited by 68
p53 gene mutation in thyroid carcinoma
Ho, Y.-S., Tseng, S.-C., Chin, T., Hsieh, L.-L., & Lin, J. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04196-1 · Cited by 58
Saenko, V., Rogounovitch, T., Shimizu‐Yoshida, Y., AIu, A., Lushnikov, E. F., Rumyantsev, P. O., Matsumoto, N., Nakashima, M., Meirmanov, S. K., Ohtsuru, A., et al. (2003) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(03)00056-3 · Cited by 52
Gene Therapy for Thyroid Cancer: Current Status and Future Prospects
Spitzweg, C., & Morris, J. C. (2004) · Thyroid · doi:10.1089/105072504323150732 · Cited by 52
Segev, D. L., Saji, M., Phillips, G., Westra, W. H., Takiyama, Y., Piantadosi, S., Smallridge, R. C., Nishiyama, R. H., Udelsman, R., & Zeiger, M. A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4882 · Cited by 49
Molecular biology of the MEN2 gene
Santoro, Melillo, R. M., Carlomagno, et al. (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00330.x · Cited by 45
Kitamura, Y., Shimizu, K., Ito, K., Tanaka, S., & Emi, M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.9.4268 · Cited by 44
The Paired Box-8/Peroxisome Proliferator-Activated Receptor-γ Oncogene in Thyroid Tumorigenesis
Reddi, H. V., McIver, B., Grebe, S. K. G., & Eberhardt, N. L. (2006) · Endocrinology · doi:10.1210/en.2006-0926 · Cited by 36
Miyake, N., Maeta, H., Horie, S., Kitamura, Y., Nanba, E., Kobayashi, K., & Terada, T. (2001) · Pathology International · doi:10.1046/j.1440-1827.2001.01269.x · Cited by 33
Cited by
Elisei, R., Ugolini, C., Viola, D., Lupi, C., Biagini, A., Giannini, R., Romei, C., Miccoli, P., Pinchera, A., & Basolo, F. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0607 · Cited by 528
Papillary Thyroid Carcinoma Variants
Lloyd, R. V., Buehler, D., & Khanafshar, E. (2011) · Head and Neck Pathology · doi:10.1007/s12105-010-0236-9 · Cited by 277
Fiore, E., Rago, T., Provenzale, M. A., Scutari, M., Ugolini, C., Basolo, F., Di Coscio, G., Berti, P., Grasso, L., Elisei, R., et al. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-09-0036 · Cited by 254
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
Capdevila, J., & Stjepanovic, N. (2014) · Biologics: Targets and Therapy · doi:10.2147/btt.s39381 · Cited by 85
PKA Activates AMPK Through LKB1 Signaling in Follicular Thyroid Cancer
Kari, S., Vasko, V. V., Priya, S., & Kirschner, L. S. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00769 · Cited by 34
Metadata
- Authors
- Nikiforova, M. N., & Nikiforov, Y. E.
- Venue
- Expert Review of Molecular Diagnostics
- Publisher
- Informa UK Limited
- Published
- 2008-01
- Volume
- 8
- Issue
- 1
- Pages
- 83-95
- ISSN
- 1473-7159 (ISSN-L)
- 1744-8352
- OpenAlex
- W2109544257
- Cited by
- 277
- References
- 115
- FWCI
- 15.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.